Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Argus Health
Harvard Business School
Boehringer Ingelheim
Novartis
Johnson and Johnson
Fish and Richardson
Federal Trade Commission
Moodys
Merck

Generated: October 22, 2017

DrugPatentWatch Database Preview

STIVARGA Drug Profile

« Back to Dashboard

Which patents cover Stivarga, and what generic Stivarga alternatives are available?

Stivarga is a drug marketed by Bayer Hlthcare and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twenty-seven patent family members in fifty-eight countries and twenty-five supplementary protection certificates in fourteen countries.

The generic ingredient in STIVARGA is regorafenib. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the regorafenib profile page.

Summary for Tradename: STIVARGA

US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list71
Clinical Trials: see list43
Patent Applications: see list53
Drug Prices:see details
DailyMed Link:STIVARGA at DailyMed

Pharmacology for Tradename: STIVARGA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
STIVARGA
regorafenib
TABLET;ORAL203085-001Sep 27, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Bayer Hlthcare
STIVARGA
regorafenib
TABLET;ORAL203085-001Sep 27, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
STIVARGA
regorafenib
TABLET;ORAL203085-001Sep 27, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Bayer Hlthcare
STIVARGA
regorafenib
TABLET;ORAL203085-001Sep 27, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
STIVARGA
regorafenib
TABLET;ORAL203085-001Sep 27, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Bayer Hlthcare
STIVARGA
regorafenib
TABLET;ORAL203085-001Sep 27, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Bayer Hlthcare
STIVARGA
regorafenib
TABLET;ORAL203085-001Sep 27, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
STIVARGA
regorafenib
TABLET;ORAL203085-001Sep 27, 2012RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for STIVARGA

Drugname Dosage Strength RLD Submissiondate
regorafenibTablets40 mgStivarga9/27/2016

Non-Orange Book Patents for Tradename: STIVARGA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,841,330Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors► Subscribe
7,528,255Hydroxy, .omega.-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors► Subscribe
7,928,239Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas► Subscribe
8,124,630.omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors► Subscribe
8,748,622Process for the preparation of 4-{4[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluor- ophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate► Subscribe
7,897,623.omega.-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: STIVARGA

Country Document Number Estimated Expiration
Czech Republic20012489► Subscribe
Slovakia9882001► Subscribe
Tunisia2012000492► Subscribe
New Zealand602997► Subscribe
TaiwanI475992► Subscribe
Brazil112012026117► Subscribe
Colombia5170439► Subscribe
TaiwanI539951► Subscribe
South Korea101091101► Subscribe
Slovenia1663978► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: STIVARGA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2006 008, C 1140840Lithuania► SubscribePRODUCT NAME: SORAFENIBAS IR FARMACINIU PO?I?RIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
2007 00002Denmark► Subscribe
90050-1Sweden► SubscribePRODUCT NAME: REGORAFENIB
5Finland► Subscribe
2006000059Germany► SubscribePRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
2006008Lithuania► SubscribePRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
1140840/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
1663978/01Switzerland► SubscribeFORMER OWNER: BAYER HEALTHCARE LLC, US
C 031/2006Ireland► SubscribeSPC 031/2006: 20070528, EXPIRES: 20210718
2013 00056Denmark► SubscribePRODUCT NAME: REGORAFENIB OG SALTE DERAF; REG. NO/DATE: EU/1/13/858 20130826
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
QuintilesIMS
US Army
Cerilliant
Federal Trade Commission
Mallinckrodt
Citi
Fish and Richardson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot